EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Double-Blind Randomized Controlled Study to Evaluate the Effect of Haimavathi Vacha Churna Capsules in Alzheimer's Disease

Megha AC, Shailesh Y

Journal of Ayurveda and Integrated Medical Sciences · 08.04.2026 · 11 (3) · 31-38

DOI: 10.21760/jaims.11.3.5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ayurveda and Integrated Medical Sciences, online erschienen am 08.04.2026. Verfasst von Megha AC und 1 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Smritibhramsha (memory impairment), characterized by progressive cognitive decline, represents a significant clinical manifestation of Alzheimer's disease in ageing populations. Conventional pharmacological interventions demonstrate limited efficacy and substantial cost burden, necessitating exploration of evidence-based traditional therapeutic options.

Aim

To assess the clinical efficacy of Haimavathi Vacha Churna capsules compared with Guduchi Kashaya Ghana capsules in the management of Smritibhramsha–Alzheimer's disease.

Methods

A prospective, double-blind, randomized controlled trial with pre- and post-treatment design was conducted on 30 patients diagnosed with Alzheimer's disease. Participants were randomly allocated into two groups (n = 15 each): Group A received Haimavathi Vacha Churna capsules, and Group B received Guduchi Kashaya Ghana capsules. Each participant received three 500 mg capsules daily on empty stomach with lukewarm water for 28 days, followed by a 28-day observational period. Outcome measures included Clinical Dementia Rating Scale (CDR), Dementia Severity Rating Scale (DSRS), Quality of Life (QoL) scales, Global Deterioration Scale (GDS), and Ayurvedic-specific cognitive parameters (Grahana, Dharana, Smarana). Statistical analyses involved the Wilcoxon signed-rank and Mann-Whitney U tests.

Results

Both groups demonstrated statistically significant improvements (P ≤ 0.0006) across all outcome measures. Haimavathi Vacha Churna showed superior quality of life improvement (24.43% patient version, 25.69% informant version) with progressive enhancement. Guduchi Kashaya Ghana achieved superior dementia severity reduction (38.53% remission on Dementia Severity Rating Scale) with more rapid initial cognitive restoration. No adverse effects were reported.

Conclusion

Both Haimavathi Vacha Churna capsules and Guduchi Kashaya Ghana capsules provide safe, effective, and statistically significant therapeutic benefits in Alzheimer's disease management. Haimavathi Vacha demonstrates superior quality-of-life outcomes, whilst Guduchi shows superior cognitive restoration. Both formulations represent evidence-based adjunctive therapies in comprehensive dementia management.

Zitieren

APA

AC, M., & Y, S. (2026). A Double-Blind Randomized Controlled Study to Evaluate the Effect of Haimavathi Vacha Churna Capsules in Alzheimer's Disease. Journal of Ayurveda and Integrated Medical Sciences, 11(3), 31-38. https://doi.org/10.21760/jaims.11.3.5

Vancouver

AC M, Y S. A Double-Blind Randomized Controlled Study to Evaluate the Effect of Haimavathi Vacha Churna Capsules in Alzheimer's Disease. Journal of Ayurveda and Integrated Medical Sciences. 2026;11(3):31-38. doi:10.21760/jaims.11.3.5

BibTeX
@article{AC2026,
  author = {AC, Megha and Y, Shailesh},
  title = {A Double-Blind Randomized Controlled Study to Evaluate the Effect of Haimavathi Vacha Churna Capsules in Alzheimer's Disease},
  journal = {Journal of Ayurveda and Integrated Medical Sciences},
  year = {2026},
  volume = {11},
  number = {3},
  pages = {31--38},
  doi = {10.21760/jaims.11.3.5}
}
Kostenlos starten →